BLTE (Belite Bio Pharma) Rasio Nilai Pasar marang Nilai Buku

Simbol resmi perusahaan Belite Bio, Inc (BLTE)

Belite Bio, Inc (BLTE) is facing a liquidity shortage and the depletion of reserves due to costs associated with final testing of its ophthalmological products. However, the development of the unique drug LBS-008 paves the way for a profitable cash flow. This price chart reflects the asset's dynamics, with a value of 7.53. The business's financial stability is currently limited by a lack of revenue and total dependence on external financing.

BLTE Belite Bio Inc: Nilai Pasar marang Nilai Buku ing interval 28.04.2023 - 28.10.2026

Rincian metrik keuangan lan pasar belitebio.com (BLTE)

- rega lan prakiraan konsensus rega:
Rega saham Belite Bio Pharma|BLTE - Rata-rata rega prakiraan
- data kapitalisasi pasar:
Nilai pasar Belite Bio Corp|BLTE - Nilai Wutuh Bisnis
- data kapitalisasi buku:
Nilai Buku saben Saham Belite Bio|BLTE - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku belitebio.com|BLTE - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Belite Bio, Inc|BLTE - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Belite Bio|BLTE - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Belite Bio Corp
Analisis wiwitan perusahaan:Belite Bio Inc - BLTE
Produk asli Belite Bio

The success of Belite Bio, Inc (BLTE) currently depends on regulatory approval of final-stage clinical trials, which renders asset values volatile. By analyzing changes in the company's P/B ratio, an investor can observe the relationship between market price and the book value of equity, allowing for an assessment of the premium paid for the business relative to its net assets and the determination of the investment's margin of safety.

Pesaing utama

Rasio Kapitalisasi Pasar marang Nilai Buku ALC|BLCO (bausch.com) - Koefisien Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Glaukos GKOS|Kapitalisasi Pasar marang Aset Bersih Apellis Pharmaceuticals, Inc.|Ocular Therapeutix Corp (OCUL) - Rasio Kapitalisasi Pasar marang Nilai Buku|Nilai Pasar marang Nilai Buku Harrow Corp (HROW)|Rasio Kapitalisasi Pasar marang Nilai Buku VRDN (Viridian Therapeutics)|lenz-tx.com - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Oaktree Specialty Lending (OCS)|EYPT: Nilai Pasar marang Nilai Buku|KOD (Kodiak Pharma) - Rasio Nilai Pasar marang Nilai Buku|Aldeyra Therapeutics, Inc. (ALDX) - Rasio Kapitalisasi marang Aset Bersih|KALA (KALA BIO Inc.) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku Opus Bio (IRD)|OKYO Pharma Limited (OKYO) - Rasio Kapitalisasi marang Aset Bersih|Nilai Pasar marang Nilai Buku adverum.com (ADVM)|OTLK: Rasio Kapitalisasi Pasar marang Nilai Buku|CLSD - Koefisien Nilai Pasar marang Nilai Buku|NBY (NovaBay) - Rasio Kapitalisasi marang Aset Bersih|KPRX - Koefisien Nilai Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku ALIM|EYEN (Eyenovia) - Koefisien Nilai Pasar marang Nilai Buku|GHSI: Rasio Nilai Pasar marang Nilai Buku|Kapitalisasi Pasar marang Nilai Buku Ocuphire Corporation|Rasio Kapitalisasi Pasar marang Nilai Buku Opthea Limited (OPT)